scholarly journals Health Economics And Radium-223 (Xofigo®) In The Treatment Of Metastatic Castration-Resistant Prostate Cancer (Mcrpc). A Case History And A Systematic Review Of The Literature On Cost-Effectiveness Analysis (Cea)

2015 ◽  
Vol 18 (7) ◽  
pp. A460-A461 ◽  
Author(s):  
J Norum ◽  
E Traasdahl ◽  
A Totth ◽  
C Nieder ◽  
JA Olsen
Keyword(s):  
Prostate Cancer ◽  
Systematic Review ◽  
Cost Effectiveness ◽  
Health Economics ◽  
Case History ◽  
Castration Resistant Prostate Cancer ◽  
Review Of The Literature ◽  
Castration Resistant ◽  
Effectiveness Analysis ◽  
Radium 223

scholarly journals Health Economics and Radium-223 (Xofigo®) in the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Case History and a Systematic Review of the Literature

2015 ◽  
Vol 8 (4) ◽  
pp. 1 ◽  
Author(s):  
Jan Norum ◽  
Erik R. Traasdahl ◽  
Arpad Totth ◽  
Carsten Nieder ◽  
Jan Abel Olsen
Keyword(s):  
Prostate Cancer ◽  
Cost Effectiveness ◽  
Health Economics ◽  
Randomized Clinical Trials ◽  
Cost Effective ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant ◽  
Radium 223 ◽  
Life Years ◽  
Google Search

<p><strong>OBJECTIVES: </strong>Prostate cancer (PC) is the most common cancer in Western countries. Recent advances in the treatment of metastatic castration resistant prostate cancer (mCRPC) have caused significant pressure on health care budgets. We aimed to exemplify this dilemma presenting an example, radium-223 (Xofigo®), and review the literature.</p> <p><strong>METHODS:</strong> A 74-year-old man diagnosed with mCRPC was referred to our department in October 2014 for radium-223 therapy. We faced the following dilemma: is radium-223 standard therapy? Is it cost-effective? Medline was searched employing the following search criteria: “radium-223”, “alpharadin”, “Xofigo” and “prostate”. Exclusion and inclusion criteria were applied. Guidelines and cost-effectiveness analyses were focused. We also searched the websites of ASCO, ESMO and ISPOR. The web was searched, using Yahoo and Google search engines, for Health Technology Assessments (HTAs).</p> <p><strong>RESULTS: </strong>181 publications were identified in the Medline database. Only four studies included the word “cost”, three “economics” and none “budget” in heading or abstract. None of the publications were thorough of cost analysis (cost-effectiveness, cost-utility, cost-minimizing or cost-of-illness analysis). Six HTAs and eight national guidelines were identified. The cost per quality adjusted life years was indicated €80.000-94,000. HTAs concluded reimbursement being not recommendable or no ultimate statement could be made. One pointed towards a limited use with caution.</p> <p><strong>CONCLUSION:</strong> Guidelines were based on data from randomized clinical trials (RCTs). Health economics was not considered when guidelines were made. Most HTAs concluded this therapy not cost-effective or there was insufficient data for final conclusions. Licensing and reimbursement processes should be run simultaneously.</p>

scholarly journals Cost-effectiveness Analysis of Radium-223 Dichloride in Metastatic Castration-Resistant Prostate Cancer Patients Without Previous Chemotherapy Treatment in Spain

10.36469/9777 ◽  
2018 ◽  
Vol 6 (1) ◽  
pp. 1-14
Author(s):  
Eva Tirado ◽  
Daniel Callejo Velasco ◽  
Marta Rubio Cabezas ◽  
Cristina Moretones Agut ◽  
Meritxell Granell Villalón
Keyword(s):  
Prostate Cancer ◽  
Cost Effectiveness ◽  
Health Outcomes ◽  
Cost Effectiveness Analysis ◽  
Castration Resistant Prostate Cancer ◽  
System Perspective ◽  
Castration Resistant ◽  
Effectiveness Analysis ◽  
Radium 223 ◽  
Docetaxel Treatment

Purpose: To perform a cost-effectiveness analysis of radium-223 plus Best Supportive Care (BSC) compared to BSC in the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) and without previous docetaxel treatment in Spain. Design and methods: A Markov model was developed to compare radium-223 versus BSC and to accrue the health outcomes and costs of a simulated cohort of mCRPC patients. Quality-adjusted life year (QALY) and life year (LY) were selected as health outcomes to measure the effectiveness of treatment alternatives. Main health resource use and efficacy inputs were obtained from a randomized controlled trial comparing radium-223 versus placebo. Unit costs were retrieved from Spanish databases and published sources. One-way and probabilistic sensitivity analyses were carried out to assess uncertainty. Results: Total costs and QALYs were €65 067 and 1.12 QALYs for radium-223 and €55 437 and 0.77 QALYs for BSC. Therefore, incremental costs per QALY were €27 606. The sensitivity analysis showed that with a willingness-to-pay threshold of €30 000 per QALY, radium-223 would have a probability of 48% of being cost-effective compared to BSC. Conclusions: Although results must be assessed with caution, from the Spanish National Health System perspective and based on the results of the present analysis, radium-223 could be a suitable option of health resources’ utilization for end of life mCRPC without previous docetaxel treatment, subject to a moderate level of uncertainty.

scholarly journals Cost-effectiveness analyses and cost analyses in castration-resistant prostate cancer: A systematic review

PLoS ONE ◽  
2018 ◽  
Vol 13 (12) ◽  
pp. e0208063 ◽  
Author(s):  
Thomas Grochtdreis ◽  
Hans-Helmut König ◽  
Alexander Dobruschkin ◽  
Gunhild von Amsberg ◽  
Judith Dams
Keyword(s):  
Prostate Cancer ◽  
Systematic Review ◽  
Cost Effectiveness ◽  
Castration Resistant Prostate Cancer ◽  
Cost Analyses ◽  
Castration Resistant

scholarly journals Economic Evaluations of Cabazitaxel for Treatment of Post-docetaxel Metastatic Castration-resistant Prostate Cancer: Evidence from a Systematic Review

2019 ◽  
pp. 1-8
Author(s):  
Nikinaz Ashrafi Shahmirzadi ◽  
Pardis Zaboli ◽  
Monireh Afzali ◽  
Bereket Molla Tigabu ◽  
Mirhamed Hajimiri ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Systematic Review ◽  
Cost Effective ◽  
Bibliographic Databases ◽  
Economic Evaluations ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant ◽  
Radium 223 ◽  
Number Of Patients ◽  
Effective Option

Background and Objectives: Prostate cancer is an ever-increasing global incidence and has become the fifth leading cause of cancer-related mortality in men. A significant number of patients with prostate cancer develop metastatic castration-resistant prostate cancer (mCRPC). There are a few second-line treatment options for patients with post-docetaxel mCRPC. This systematic review aimed to assess the cost-effectiveness of cabazitaxel for the treatment of mCRPC. Materials and Methods: Electronic bibliographic databases including: PubMed/Medline, NICE, CRD, and Scopus were searched in January 2018 for identifying full economic evaluations published in English and Persian. The risk of assessment bias and descriptive analyses of individual studies’ findings were presented. Results: Three articles that fulfilled the inclusion criteria were included in the current study. All the included records had a reasonable quality. Cabazitaxel was not recommended as the most cost-effective option for the treatment of docetaxel-refractory mCRPC. Abiraterone acetate and radium-223 were the recommended cost-effective treatments for mCRPC treatment. Conclusion: We found that, in general, while cabazitaxel had equal or slightly higher improvement in Quality-adjusted Life Year (QALY) as compared to the alternatives, it incurred a high cost. Despite the inclusion of a few studies in this review, cabazitaxel was not found to be a cost-effective option. Therefore, we recommend full economic evaluations to be conducted in this area.

Sign in / Sign up

Export Citation Format

Share Document